For instance, changes (e.g., mutation and methylation) in the serum DNAs (ctDNAs), such as MGMT 7-9, EGFR 10, and PTEN 9, have been proven to be effective biomarkers of glioma and may have the potential for the diagnosis of glioma. This evidence concerns the gene EGFR and central nervous system cancer.